Actively Recruiting
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
Led by Taichung Veterans General Hospital · Updated on 2026-05-14
140
Participants Needed
1
Research Sites
593 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.
CONDITIONS
Official Title
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients more than 20 years old
- Chronic hepatitis B patients
- Patients who were indicated for hepatitis B virus antiviral therapy
You will not qualify if you...
- Decompensated liver disease (Child-Pugh B & C)
- End stage renal disease (eGRF < 15 ml/min/1.73m2)
- Prior use of nucleot(s)ide analogues for chronic hepatitis B
- Prior use of interferon for chronic hepatitis B within six months
- Known history of human immunodeficiency virus or hepatitis C virus co-infection
- Concurrent other uncontrolled malignancy
- Women in pregnancy or lactation
- Cannot conform to the study protocol of this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Taichung Veterans General Hospital
Taichung, Taichung, Taiwan
Actively Recruiting
Research Team
T
Teng-Yu Lee, MD, PhD
CONTACT
H
Hsin-Ju Tsai, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here